ArticleFrontiers in oncology2022

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring

Zhan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.